title: [Treatment of nongonococcal urethritis--studies on clinical effects of ofloxacin].
abstract: Clinical effects of ofloxacin (OFLX) in the treatment of chlamydial urethritis was compared with those in the treatment of non-chlamydial urethritis. Chlamydia trachomatis was isolated from 33 (39.3%) out of 84 patients with nongonococcal urethritis. OFLX was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 patients with chlamydial urethritis, C. trachomatis was eliminated within 7 to 14 days after the start of administration, and, in two patients, inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and pyuria in VB1 of the patients with chlamydial urethritis, disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the patients with non-chlamydial urethritis, urethral discharge, PMNL, and pyuria in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of OFLX between cases of chlamydial urethritis and those of non-chlamydial urethritis. Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and non-chlamydial urethritis. In nine out of 11 cases of non-chlamydial urethritis where OFLX was ineffective, no Ureaplasma nor aerobes, nor C. trachomatis, were isolated. In the remaining two cases where Ureaplasma and S. epidermidis were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: I
authors.initials: I
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Terada
authors.forename: Y
authors.initials: Y
authors.lastname: Kunisawa
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D010078:Oxazines; D015242:Ofloxacin